www.onkologiecs.cz ONKOLOGIE 101 MONOKLONÁLNÍ GAMAPATIE Waldenströmova makroglobulinemie, klinické příznaky, přehled léčebných možností a vlastní zkušenosti s léčbou ibrutinibem 100. Chen C, Kouroukis CT, White D, et al. Bortezomib in relapsed or refractory Waldenstrom‘s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:74-76. 101. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol. 2010;85:670-674. 102. Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrommacroglobulinemia patients. Blood. 2018;132:2608-2612. 103. Gavriatopoulou M, Garcia-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017;129:456-459. 104. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-termresults of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122(19):32763282. doi: 10.1182/blood-2013-05-503862. 105. Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132:547-550. 106. Berentsen S, Barcellini W, D´SA S, et al. Cold agglutinin disease revisited: a multinational observational study of 232 pacients. Blood. 2022;136(4):480-488. 107. Kong D, Li Y, Fu C, Hou M, Yan L. Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom‘s macroglobulinemia. Leuk Lymphoma. 2022;63(2):491494. doi: 10.1080/10428194.2021.1992766. Epub2021 Oct 20. PMID: 34668450. 108. Ojeda-Uribe M, Rimelen V, Marzullo C. Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome. J Blood Med. 2020;11:67-72. doi: 10.2147/ JBM.S233059. PMID: 32104129; PMCID: PMC7025649. 109. Zhang YP, Yang X, Lin ZH, Wang XF, Cao X, You XF, Huang HM, Shi WY, Liu H. Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenström macroglobulinemia. Eur J Haematol. 2017;99(6):489-494. doi: 10.1111/ejh.12935. Epub 2017 Sep 13. PMID: 28801984. 110. Leblond V, Morel P, Dilhuidy MS. French Innovative Leukemia Organization (FILO). A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. Leuk Lymphoma. 2017;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. 111. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström‘s macroglobulinemia. Blood. 2014;124(4):503-510. doi: 10.1182/blood-2014-03-566273. 112. Vesole DH, Richter J, Biran N, et al. Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. Leuk Lymphoma. 2018;59(1):259-261. doi: 10.1080/10428194.2017.1321749. 113. Chaudhry M, Steiner R, Claussen C, et al. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstrom‘s macroglobulinemia. Leuk Lymphoma. 2019;60:964-970. 114. Castillo JJ, Meid K, Catherine A, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow- -up. Blood Adv. 2020;4(16):3952-3959. doi: 10.1182/bloodadvances.2020001963. 115. Kersten MJ, Amaador K, Minnema MC, et al. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström‘s Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ ECWM-R2 Study. J Clin Oncol. 2022;40(1):40-51. doi: 10.1200/JCO.21.00105. 116. Ma W, Zhao J, Zhang L. A Promising New Therapy of Oral Ixazomib Without Rituximab for WaldenstromMacroglobulinemia. Turk J Haematol. 2021;38(1):87-89. doi: 10.4274/tjh.galenos.2020.2020.0521. 117. Kastritis E, Dimopoulos MA. Proteasome Inhibitors in WaldenströmMacroglobulinemia. Hematol Oncol Clin North Am. 2018;32(5):829-840. doi:10.1016/j.hoc.2018.05.011. 118. Fečková-Mihályová J Ďuraš J, Zuchnická J, et al. Ibrutinib v hematoonkologii. Klinická farmakologie a farmacie. 2016;30(3):8-14. 119. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom‘s macroglobulinemia. N Engl J Med. 2015;372:1430-1440. 120. Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with Ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17:31-37. 121. Gustine JN, Meid K, Dubeau T, et al. Ibrutinib discontinuation in Waldenstrommacroglobulinemia: etiologies, outcomes, and IgM rebound. Am J Hematol. 2018;93: 511-517. 122. Treon SP, Xu L, Hunter Z. MYD88 mutations and response to Ibrutinib in Waldenstrom‘s macroglobulinemia. N Engl J Med. 2015;373:584-586. 123. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom‘s macroglobulinaemia. (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241-250. 124. Treon SP, Gustine J, Meid K, et al. Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom‘s macroglobulinemia. Blood. 2017;130:2767-2767. 125. Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2018;36(27):2755-2761. 126. Abeykoon JP, Zanwar S, Ansell SM, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2020;188:394-403. 127. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom‘s macroglobulinemia. N Engl J Med. 2018;378:2399-2410. 128. Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström‘s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2022;40(1):52-62. doi: 10.1200/JCO.21.00838. 129. Castillo JJ, Gustine JN, Meid K, et al. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia. Haematologica. 2018;103:e466-e468. 130. Castillo JJ, Gustine JN, Meid K, et al. Ibrutinib withdrawal symptoms in patients with Waldenstrommacroglobulinemia. Haematologica. 2018;103:e307-e310. 131. Migkou M, Fotiou D, Gavriatopoulou M, et al. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström‘s macroglobulinemia: a safety evaluation. Expert Opin Drug Saf. 2021;20(9):987-995. doi: 10.1080/14740338.2021.1945031. 132. Castillo JJ, Abeykoon JP, Gustine JN, et al. Partial response or better at six months is prognostic of superior progression-free survival in Waldenströmmacroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021;192(3):542550. doi: 10.1111/bjh.17225. 133. Castillo JJ, Meid K, Gustine JN, et al. Treon SP. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022;36(2):532-539. doi: 10.1038/s41375-021-01417-9. 134. Castillo JJ, Sarosiek SR, Gustine JN, et al. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022;6(3):1015-1024. doi: 0.1182/bloodadvances.2021006106.PMID: 34965304. 135. Treon SP, Meid K, Gustine J, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously TreatedPatients With WaldenströmMacroglobulinemia. J Clin Oncol. 2021;39(6):565-575. doi: 10.1200/JCO.20.00555 136. Trotman J, Buske C, Tedeschi A, et al. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> Trial. Clin Cancer Res. 2021;27(21):57935800. doi: 10.1158/1078-0432.CCR-21-1497. 137. Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56-63. doi: 10.1016/j. critrevonc.2019.02.001. 138. Ganatra S, Sharma A, Shah S, et al. Ibrutinib- Associated Atrial Fibrillation. JACC Clin Electrophysiol. 2018;4(12):14911500. doi: 10.1016/j.jacep.2018.06.004. 139. Abbas HA, Wierda WG. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. Front Oncol. 2021;11:668162. doi: 10.3389/ fonc.2021.668162. eCollection 2021. 140. Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7(2):e112-e121. 141. Tam CS, Opat S, D‘Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenströmmacroglobulinemia: the ASPEN study. Blood. 2020;136(18):20382050. doi: 10.1182/blood.2020006844. 142. TamCS, LeBlond V, Novotny W, et al. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Future Oncol. 2018;14(22):2229-2237. doi: 10.2217/fon-2018-0163. 143. Dimopoulos M, Sanz RG, Lee HP, Trněný M, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 202;4(23):6009-6018. doi: 10.1182/bloodadvances.2020003010. 144. Argyropoulos KV, Palomba ML. First-Generation and Second-Generation BrutonTyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012. 145. Munakata W, Tobinai K. Tirabrutinib hydrochloride for B-cell lymphomas. Drugs Today (Barc). 2021;57(4):277-289. doi: 10.1358/dot.2021.57.4.3264113. 146. Castillo JJ, Allan JN, Siddiqi T, et al. Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol. 2022;40(1):63-71. doi: 10.1200/JCO.21.01194. 147. Novák J, Havrda M, Gahérová Ľ, et al. Clinical case: idelalisib-induced immunoglobulin flare. Immunopharmacology and immunotoxicology. 2017;39(4):251-255. 148. Belada D. Idelalisib v léčbě pacientů s folikulárním lymfomem. Farmakoterapie. 2015;11(3):292-296. 149. Kyriakou C. High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018;32(5):865-874. doi: 10.1016/j.hoc.2018.05.013. 150. Kaščák M, Ďuraš J, Navrátil M, et al. Autologní transplantace kmenových buněk u Waldenströmovy makroglobulinemie. Transfuze a hematologie dnes. 2016;22(1):28-38. 151. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrommacroglobulinemia. Blood. 2009;113:4163-4170. 152. Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, et al. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia. 2019;33(11):2654-2656. 153. Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenströmmacroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022;197(2):171187. doi: 10.1111/bjh.18036. 154. Migkou M, Fotiou D, Gavriatopoulou M, et al. Ibrutinib plus rituximab for the treatment of adult patients
RkJQdWJsaXNoZXIy NDA4Mjc=